4.1 Article

A high-throughput MALDI-TOF MS biochemical screen for small molecule inhibitors of the antigen aminopeptidase ERAP1

Journal

SLAS DISCOVERY
Volume 28, Issue 1, Pages 3-11

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.slasd.2022.11.002

Keywords

MALDI-TOF MS; High-throughput screening; Drug discovery; Mass spectrometry; Endoplasmic reticulum aminopeptidase 1; Major histocompatibility complex

Ask authors/readers for more resources

This article describes the development of a novel, high-throughput screening method based on MALDI-TOF MS for fast and label-free drug discovery of ERAP1. The peptide YTAFTIPSI was trimmed into TAFTIPSI to improve ionization efficiency. The optimal conditions for the new assay were established on the MALDI-TOF MS platform and compared to the established RF MS setup, showing comparable performance with several advantages for the MALDI-TOF MS platform.
MALDI-TOF MS is a powerful analytical technique that provides a fast and label-free readout for in vitro assays in the high-throughput screening (HTS) environment. Here, we describe the development of a novel, HTS compat-ible, MALDI-TOF MS-based drug discovery assay for the endoplasmic reticulum aminopeptidase 1 (ERAP1), an important target in immuno-oncology and auto-immune diseases. A MALDI-TOF MS assay was developed begin-ning with an already established ERAP1 RapidFire MS (RF MS) assay, where the peptide YTAFTIPSI is trimmed into the product TAFTIPSI. We noted low ionisation efficiency of these peptides in MALDI-TOF MS and hence incorporated arginine residues into the peptide sequences to improve ionisation. The optimal assay conditions were established with these new basic assay peptides on the MALDI-TOF MS platform and validated with known ERAP1 inhibitors. Assay stability, reproducibility and robustness was demonstrated on the MALDI-TOF MS plat-form. From a set of 699 confirmed ERAP1 binders, identified in a prior affinity selection mass spectrometry (ASMS) screen, active compounds were determined at single concentration and in a dose-response format with the new MALDI-TOF MS setup. Furthermore, to allow for platform performance comparison, the same compound set was tested on the established RF MS setup, as the new basic peptides showed fragmentation in ESI-MS. The two platforms showed a comparable performance, but the MALDI-TOF MS platform had several advantages, such as shorter sample cycle times, reduced reagent consumption, and a lower tight-binding limit.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available